Senseonics Q3 2026: Revenue Surges 141% After Eversense Goes Direct

Senseonics reported third-quarter 2026 revenue of $19.56 million, beating the $16.20 million consensus and marking 141.6% growth compared with the same period a year earlier. The loss per share of $0.50 came in better than the $0.52 estimate, a 4.2% beat. Both figures reflect a business in rapid commercial transition.

The single biggest driver of the quarter was Senseonics' decision to bring U.S. commercial operations for its Eversense 365 implantable continuous glucose monitor in-house, replacing what had been a lower-margin partner distribution arrangement. U.S. revenue reached $16.80 million, up roughly 160% year over year, on record quarterly shipment volume. Active prescribers grew approximately 90% year over year, suggesting the direct sales push is reaching new corners of the diabetes care market.

Taking distribution in-house also restructured the economics of each dollar sold. Gross margin expanded to roughly 62% from 43% a year earlier, a nearly 20-percentage-point swing that transforms how much of the top-line growth flows toward narrowing the company's operating loss. The EON Care inserter network, which performed over 40% of Q3 Eversense insertion procedures, now counts more than 100 sites, and management raised its year-end target to 120.

Management raised full-year 2026 revenue guidance to $68 million to $70 million, up from a prior range of $62 million to $66 million. At the midpoint that implies 93% to 98% year-over-year growth for the full year. Full-year gross margin guidance was also lifted to above 60%, from a prior range of 58% to 61%.

Looking further out, Senseonics has a commercial launch of the Eversense 365 integration with Beta Bionics' iLet Bionic Pancreas automated insulin delivery system planned for the fourth quarter of 2026. The company also initiated a first-in-human study of Freedom, an investigational next-generation CGM designed to communicate directly with a mobile device without any on-body component. These pipeline milestones matter because the addressable market for CGM options that reduce device burden is a cited tailwind in management's own framing.

The risks worth tracking include the widening net loss, which reflects elevated selling, general, and administrative spending tied to the commercial build-out, as well as execution risk in the European commercial transition and dependence on partners to complete automated insulin delivery integrations. Cash and equivalents stood at $47.76 million at quarter end, up 37.35% year over year, providing some runway, though the company carries obligations under the Hercules Capital debt facility.